Upamostat
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C32H47N5O6S |
Molar mass | 629.82 g·mol−1 |
3D model (JSmol) | |
| |
|
Upamostat (WX-671, Mesupron) is a drug which acts as an inhibitor of the serine protease enzyme urokinase. It is under development as a potential treatment agent for pancreatic cancer, acting to inhibit tumour metastasis.[1][2][3]
References
- ^ Kuş C, Özer E, Korkmaz Y, Yurtcu E, Dağalp R (2018). "Benzamide and Benzamidine Compounds as New Inhibitors of Urokinasetype Plasminogen Activators". Mini Reviews in Medicinal Chemistry. 18 (20): 1753–1758. doi:10.2174/1389557518666180816110740. PMID 30112993. S2CID 52011447.
- ^ Heinemann V, Ebert MP, Laubender RP, Bevan P, Mala C, Boeck S (March 2013). "Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer". British Journal of Cancer. 108 (4): 766–70. doi:10.1038/bjc.2013.62. PMC 3590684. PMID 23412098.
- ^ Froriep D, Clement B, Bittner F, Mendel RR, Reichmann D, Schmalix W, Havemeyer A (September 2013). "Activation of the anti-cancer agent upamostat by the mARC enzyme system". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 43 (9): 780–4. doi:10.3109/00498254.2013.767481. PMID 23379481. S2CID 20052617.